Quoin Pharmaceuticals shares are trading higher after the company announced it received FDA clearance to initiate a second whole-body QRX003 netherton syndrome clinical study.
Quoin Pharmaceuticals shares are trading higher after the company announced it received FDA clearance to initiate a second whole-body QRX003 netherton syndrome clinical study.